Viking also announced Tuesday that it is planning to begin a Phase 1 trial of an oral version of VK2735. In a statement, Viking said the side effect data suggests it could increase doses higher with a longer build-up period, an approach the company may try in a Phase 2 trial. In testing its GLP-1/GIP drug, Viking avoided the fate of another company called Altimmune, which last week reported high dropout rates due to side effects in a trial of a similar weight loss drug. Diva Diva Pictures, Images and Stock Photos View diva videos Browse 12,100+ diva stock photos and images available, or search for diva crown or opera diva to find more great stock photos and pictures. One participant with a history of gallstones experienced a case of gall bladder obstruction, Viking said. Side effects of the experimental drug included mild and moderate nausea, a common complaint of this class of drugs, but no one stopped treatment because of this side effect. By comparison, the six patients given 5 milligram weekly dose and later 10 milligrams experienced a 7.8% lowering in body weight, which was considered a statistically significant difference versus placebo. Six people randomized to receive 0.5 milligrams of VK2735 during the four weeks of the trial lost 2.5% of their body weight, compared with 1.8% in the placebo arm, a difference that was not statistically significant. Ten participants also received a placebo. Viking’s two-part study first enrolled adults to receive single doses of VK2735 to evaluate its safety and biologic activity, then enrolled people diagnosed as obese to take increasing weekly doses over four weeks. Lilly’s Mounjaro stimulates a second one, dubbed GIP, and Viking - better known for development of an experimental drug for the liver disease NASH - is trying to duplicate that treatment approach. Those drugs activate only one insulin-secreting hormone, called GLP-1. (Ozempic is also being used off-label as a weight loss drug as demand has outstripped Novo’s supply.) It followed on that success years later with a weekly shot, marketed as Ozempic for diabetes and Wegovy for weight loss. Novo Nordisk pioneered the use of insulin-stimulating diabetes drugs as weight loss treatments when it launched a high-dose version of its daily shot Victoza as Saxenda in 2014.
0 Comments
Leave a Reply. |